LIVER**STAT**

A Screening Test for
Non-Alcoholic Fatty Liver Disease
(NAFLD) and Liver Fibrosis

unicus
med

LIVERSTAT as your first-line screening test for NAFLD and NASH in Metabolic Syndrome (MetS) patients

80%

of patients with NAFLD present with normal liver enzymes and **are underdiagnosed**[1-2]

Up to 56%

develop NASH in cases of NAFLD especially in the presence of type 2 diabetes[3]

1 in 3

patients with diabetes present with normal ALT despite **advanced fibrosis**[4]

A liver ultrasound **cannot stage liver fibrosis**[5]

What is LIVERSTAT ?

LIVERSTAT is a blood-based test combining common biomarkers using AI technology for clinical screening in subjects having MetS risk of NAFLD-NASH

No NAFLD	NAFL	NASH without bridging fibrosis	NASH with bridging fibrosis ▼
Stage N0	**Stage N1**	**Stage N2**	**Stage N3**

Managing NAFLD risk with LIVERSTAT

- **LIVERSTAT** for all MetS patients as first-line screening

- Receive **LIVERSTAT** report for:
  - **N3** - presumed Fibrosis F3F4 stage
  - **N2** - presumed fibrosis without F3F4 stage
  - **N1** - presumed steatosis without fibrosis (NAFL)
  - **N0** -Normal liver, no fibrosis, no steatosis

- **Determine** the best patient management plan:
  - Intensive lifestyle change
  - MetS correction
  - Referral to liver specialist
  - Monitor progression with LIVERFASt[6]

Simple and Convenient with Immediate Results

Physician prescribes **LIVERSTAT** for the patient

Lab analyses 7 biomarkers from **1 blood sample**

Biomarker results and **patient specific characteristics** input into Fibronostics' proprietary Artificial Intelligence (AI) platform

LIVERSTAT results are **available immediately**

High-risk conditions in population to screen for NAFLD

Obesity | **Diabetes** | **Hypertension** | **Dyslipidemia** | **OSA*** | **Bariatric Surgery** | **PCOS***

* **OSA** Obstructive Sleep Apnea; **PCOS** Polycystic Ovarian Syndrome

7 Blood biomarker:

- Triglycerides
- Total Cholesterol
- Fasting glucose
- Total Bilirubin
- AST
- ALT
- GGT

4 Anthropometrics:

- Age (Date of Birth)
- Weight
- Height
- Gender

High performance for severe fibrosis detection

AUROC (95% CI) for bridging fibrosis (F3F4)

	Training cohort N=270	Validation cohort N-310
LIVERFASt GP+	0.806 (0.737 - 0.841)	**0.759** (0.701 - 0.808)
FIB-4	0.807 (0.630 - 0.756)	**0.757** (0.698 - 0.805)
P value	NS	NS

Compared to FIB-4, LIVERSTAT has several advantages:

- Identifies NAFLD from fatty liver to bridging Fibrosis
- No grey zone
- Analytically calibrated
- No drawbacks related to age or diabetes
- Predicts outcomes for COVID-19 by identifying liver fibrosis7

> " Look for NAFLD in patients with Type 2 Diabetes Mellitus, irrespective of liver enzyme levels, due to high risk of disease progression.[8]
>
> EASL-ILC, 2016

25%

of people with Metabolic Syndrome risk factors* have non-alcoholic fatty liver disease (NAFLD).
Prevalence of NAFLD in patients with Type 2 Diabetes is two times higher than in the general population.

30%

of people with fat droplets in their liver cells develop non-alcoholic steatohepatitis (NASH), where the liver becomes inflamed and the hepatocytes suffer from ballooning.[3,9]

## 20%

of people with NASH will develop scarring (fibrosis) of the liver and the hepatocytes suffer from ballooning.[3,10]

▶▶ NAFLD   ▶▶ NASH   ▶▶

Healthy Liver   **Simple Fatty Liver**   **Fatty Liver with Inflammation /Scarring**   **Liver Cirrhosis**

FIBRONOSTICS

LIVER**STAT**

SAMPLE RESULT SHEET

Test id: 45326
Reference no: US20210311000754

PATIENT NAME:

PHYSICIAN NAME:

JOHN SMITH M.D., P.A.

DATE OF BIRTH:	GENDER:	HEIGHT:	WEIGHT:	BMI:	DATE TEST TAKEN:
January 1, 1962	Male	1.7m	85kg	29.4	January 1, 2022

TEST SCORE

No NAFLD	NAFL ▼	NASH without bridging fibrosis	NASH with bridging fibrosis
Stage N0	Stage N1	Stage N2	Stage N3

INTERPRETATION

Presumed steatosis (non-alcoholic fatty liver, NAFL) without presumed liver fibrosis

BIOMARKER RESULTS

AGE:	60 years old	GENDER:	Male	BODY MASS INDEX:	29.4

Sample Date: Jan 1, 2022

	Result	Unit		Result	Unit
Total Bilirubin	10.0	µmol/L	Fasting Glucose	5.80	mmol/L
GGT	20	IU/L	Total Cholesterol	6.30	mmol/L
ALT	24	IU/L	Triglycerides	2.45	mmol/L
AST	39	IU/L			

Warnings: None

This report is computer generated. No signature required.

---

unicus
MARKETING MANAGEMENT LLC

Contact Us

For business enquiries: **info@unicusmed.com**

For medical and scientific enquiries: **service@fibronostics.com**

FIBRONOSTICS

Fibronostics specializes in algorithm-based noninvasive diagnostic solutions.

For more information, please visit
www.fibronostics.com

References:
1. Daniel, Am J Gastroenterol. 1999
2. Sorrentino, J Hepatol. 2004
3. Younossi ZM, J Hepatol. 2019
4. De Lédinghen V, Dig Liver Dis 2012
5. Chalassani, Hepatology 2018
6. Decraecker, Aliment Pharmacol Ther 2022
7. Sandulescu, Hepatology (Suppl) 2022
8. European Association for the Study of the Liver (EASL). "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease." Journal of Hepatology. 2016 June; 64(6):1388-402
9. Sarah, D. "Disease progression: Divergent paths." Nature. 2017 November; 551: S92-S93
10. European Association for the Study of the Liver (EASL). "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease." Journal of Hepatology. 2016 June; 64(6):1388-402

Abbreviations
AI Artificial inteligence
ALT Alanine aminotransferase
AST Aspartate aminotransferase
GGT Gamma glutamyl transpeptidase
MetS Metabolic syndrome
OSA Obstructive sleep apnea
PCOS Polycystic ovary syndrome
NAFL Non-alcoholic Fatty liver
NAFLD Non-alcoholic Fatty liver disease
NASH Non-alcoholic Steatohepatitis